Denault Marie-Hélène, Kuang Shelley, Shokoohi Aria, Leung Bonnie, Liu Mitchell, Berthelet Eric, Laskin Janessa, Sun Sophie, Zhang Tina, Melosky Barbara, Ho Cheryl
Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
Quebec Heart and Lung Institute, Québec City, Québec, Canada.
JTO Clin Res Rep. 2022 Mar 30;3(5):100316. doi: 10.1016/j.jtocrr.2022.100316. eCollection 2022 May.
Durvalumab 10 mg/kg every 2 weeks for 1 year after chemoradiation has improved overall survival (OS) in unresectable stage III NSCLC. Subsequently, a 20 mg/kg 4-weekly regimen was approved. The study goal was to compare the efficacy and toxicity of the two regimens.
All patients with NSCLC treated with curative-intent chemoradiation followed by durvalumab from March 1, 2018 to December 31, 2020 at BC Cancer, British Columbia, Canada were included in this retrospective review. Durvalumab dosing schedule, toxicity, progression, and OS were collected. Comparisons between treatment groups were made using chi-square and independent tests. Kaplan-Meier curves and log-rank test were used to analyze OS.
A total of 152 patients were included in the 2-weekly group and 53 patients in the 4-weekly group. The median follow-up was 19.7 months and 12.0 months, respectively. The median OS was not reached, but 12-month survival rates were 88.4% versus 85.2% ( = 0.55). Toxicity profiles were similar in terms of sites and severity.
There was no significant difference in efficacy or toxicity between the 2-weekly and 4-weekly durvalumab in this cohort of patients with advanced NSCLC previously treated with curative-intent chemoradiation.
在同步放化疗后每2周使用10 mg/kg度伐利尤单抗持续1年，可改善不可切除的III期非小细胞肺癌（NSCLC）患者的总生存期（OS）。随后，一种每4周使用20 mg/kg的方案获批。本研究的目的是比较这两种方案的疗效和毒性。
本回顾性研究纳入了2018年3月1日至2020年12月31日在加拿大不列颠哥伦比亚省癌症中心接受根治性同步放化疗后使用度伐利尤单抗治疗的所有NSCLC患者。收集度伐利尤单抗的给药方案、毒性、疾病进展和总生存期数据。治疗组之间的比较采用卡方检验和独立样本t检验。采用Kaplan-Meier曲线和对数秩检验分析总生存期。
每2周给药组共纳入152例患者，每4周给药组共纳入53例患者。中位随访时间分别为19.7个月和12.0个月。总生存期未达到中位数，但12个月生存率分别为88.4%和85.2%（P = 0.55）。毒性反应的部位和严重程度相似。
在这组先前接受过根治性同步放化疗的晚期NSCLC患者中，每2周和每4周使用度伐利尤单抗的疗效和毒性无显著差异。
